Leelyn Smith LLC Increases Stake in GE HealthCare Technologies Inc. (NASDAQ:GEHC)

Leelyn Smith LLC increased its holdings in GE HealthCare Technologies Inc. (NASDAQ:GEHC) by 4.2% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 42,701 shares of the company’s stock after acquiring an additional 1,727 shares during the quarter. Leelyn Smith LLC’s holdings in GE HealthCare Technologies were worth $3,338,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in GEHC. Cathy Pareto & Associates Inc. purchased a new stake in shares of GE HealthCare Technologies in the 4th quarter worth approximately $670,000. LMR Partners LLP bought a new position in GE HealthCare Technologies in the third quarter worth approximately $7,387,000. Principal Financial Group Inc. lifted its holdings in GE HealthCare Technologies by 1.9% during the third quarter. Principal Financial Group Inc. now owns 1,009,910 shares of the company’s stock worth $94,780,000 after buying an additional 19,010 shares during the period. B. Metzler seel. Sohn & Co. Holding AG bought a new stake in GE HealthCare Technologies during the 3rd quarter valued at $1,396,000. Finally, Everence Capital Management Inc. increased its holdings in shares of GE HealthCare Technologies by 118.2% in the 4th quarter. Everence Capital Management Inc. now owns 18,870 shares of the company’s stock valued at $1,475,000 after acquiring an additional 10,220 shares during the period. 82.06% of the stock is currently owned by institutional investors.

GE HealthCare Technologies Price Performance

Shares of GEHC opened at $82.47 on Tuesday. The company has a debt-to-equity ratio of 0.88, a current ratio of 1.04 and a quick ratio of 0.83. The company’s fifty day moving average price is $87.27 and its 200-day moving average price is $86.12. GE HealthCare Technologies Inc. has a 1-year low of $74.51 and a 1-year high of $94.80. The firm has a market capitalization of $37.71 billion, a PE ratio of 19.05, a price-to-earnings-growth ratio of 3.19 and a beta of 1.13.

GE HealthCare Technologies (NASDAQ:GEHC) last issued its quarterly earnings results on Thursday, February 13th. The company reported $1.45 EPS for the quarter, topping analysts’ consensus estimates of $1.26 by $0.19. The company had revenue of $5.32 billion during the quarter, compared to analysts’ expectations of $5.33 billion. GE HealthCare Technologies had a return on equity of 25.74% and a net margin of 10.13%. On average, equities research analysts predict that GE HealthCare Technologies Inc. will post 4.68 EPS for the current year.

Analyst Ratings Changes

A number of equities research analysts recently weighed in on the company. Jefferies Financial Group upgraded GE HealthCare Technologies from a “hold” rating to a “buy” rating and upped their price objective for the stock from $95.00 to $103.00 in a research note on Wednesday, January 8th. Wells Fargo & Company increased their price target on shares of GE HealthCare Technologies from $96.00 to $103.00 and gave the company an “overweight” rating in a research report on Friday, February 14th. Citigroup lifted their price objective on shares of GE HealthCare Technologies from $103.00 to $110.00 and gave the stock a “buy” rating in a research report on Thursday, February 13th. Finally, The Goldman Sachs Group raised shares of GE HealthCare Technologies from a “neutral” rating to a “buy” rating and increased their target price for the company from $85.00 to $100.00 in a research report on Tuesday, March 11th. One research analyst has rated the stock with a sell rating, two have given a hold rating, nine have assigned a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, GE HealthCare Technologies currently has a consensus rating of “Moderate Buy” and a consensus price target of $98.75.

GE HealthCare Technologies Profile

GE HealthCare Technologies Inc engages in the development, manufacture, and marketing of products, services, and complementary digital solutions used in the diagnosis, treatment, and monitoring of patients in the United States, Canada, and internationally. The company operates through four segments: Imaging, Ultrasound, Patient Care Solutions, and Pharmaceutical Diagnostics.